AbCellera Biologics
ABCL
ABCL
146 hedge funds and large institutions have $338M invested in AbCellera Biologics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 47 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
less call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $547M → $338M (-$209M)
Holders
146
Holding in Top 10
2
Calls
$1.08M
Puts
$1.16M
Top Buyers
| 1 | +$13.6M | |
| 2 | +$2.1M | |
| 3 | +$1.72M | |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.67M |
| 5 |
EAM
Exome Asset Management
New York
|
+$1.52M |
Top Sellers
| 1 | -$10.7M | |
| 2 | -$8.98M | |
| 3 | -$3.76M | |
| 4 |
Man Group
London,
United Kingdom
|
-$3.5M |
| 5 |
Lazard Asset Management
New York
|
-$2.75M |